ALFA Finder| Revenue growth | 18.8% YoY consolidated; 25.8% YoY standalone. |
|---|---|
| Margins | Sequential recovery to 10.9% consolidated EBITDA margin. |
| Order book | Decent order book currently for international business. |
| Demand visibility | Strong Rx growth in India; decent order book for UK/Europe. |
| Management confidence | High for international markets; recovery expected in domestic seasonal products. |
Growth
Consolidated revenue grew 18.8% YoY. Standalone EBITDA jumped to ₹630m (14.7% margin) from ₹35m YoY.
Outlook
Debt repayment target of ₹140cr/year for 3 years; focus on liquid orals in US/Europe; no major capex planned.
Risks
Substantial forex losses (₹24cr), high debt levels (₹960cr), and regulatory delays at sterile manufacturing sites.
Earnings Call filed with BSE, NSE: INDOCO. Summary written with AI assistance from the document.
Indoco Remedies Ltd: key numbers
- Share price
- ₹222.50
- Market cap
- ₹2,054 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 64.3×Sector 43.8×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Promoter Buying: ₹0.45 Cr
Four Indoco Remedies promoters bought 20,740 shares on NSE on 5 November 2026. Aggregate purchase value is about Rs.0.45 Crore.
- Value
- ₹0.45 Cr
Indoco Remedies Promoter Buying: ₹0.03 Cr
Indoco Remedies promoter and director Suresh G Kare bought 1,335 equity shares on the open market on 6 November 2026, raising holding from 1.42% to 1.42%. The trade value is Rs.2,84,248, about Rs.0.03 Crore.
- Value
- ₹0.03 Cr
Indoco Remedies Promoter Buying: ₹0.13 Cr
Indoco Remedies promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a combined 5,996 equity shares via market purchase. The total transaction value is ₹0.13 Crore.
- Value
- ₹0.13 Cr
- Promoter stake change
- +0.01%
Indoco Remedies Promoter Buying: ₹0.17 Cr
Indoco Remedies' promoters Aditi Panandikar and Madhura Suresh Kare acquired 8,004 shares via market purchase. The total transaction value is ₹0.17 Crore.
- Value
- ₹0.17 Cr
Indoco Remedies Earnings Call Transcript: Key Takeaways
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
- Call
- Guides 10% growth
Indoco Remedies Business Update
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.